- Microbial-Derived Metabolites and Their Impact on Cancer Immunotherapyby inmunoadminCancer Immunol Res. 2026 Jan 9:OF1-OF11. doi: 10.1158/2326-6066.CIR-25-1018. Online ahead of print. ABSTRACT The gut microbiome has emerged as a modulator of both cancer progression and patient responses to therapies like immune checkpoint inhibitors (ICI). Recent evidence highlights microbially derived metabolites as key regulators of immune response and tumor microenvironment dynamics. This review explores the … Read more
- Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitationsby inmunoadminBackground Engineering chimeric antigen receptor (CAR) T cells with logic-gated synthetic Notch (synNotch) receptor circuits can enhance specificity and mitigate on-target/off-tumor toxicity. However, the conventional synNotch system uses two lentivir…
- ROSE12, a novel anti-CTLA-4 Fc{gamma}Rs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activationby inmunoadminBackground Intratumoral regulatory T cells (Tregs) are associated with diminished antitumor immunity and poor prognosis in many cancers, with tumor-infiltrating effector Tregs expressing high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA…
- Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platformsby Santos, G. N. D. S., DeJohn, C., Hess, S. M., Zsiros, E., McGray, A. J. R.Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors, including tumor heterogeneity, immune exclusion, and a profoundly…
- T cell competition in multi-neoantigen cancer vaccinesby Emery HoosNature Reviews Immunology, Published online: 09 January 2026; doi:10.1038/s41577-026-01264-8A preprint by McCarron et al. investigates immunodominance hierarchies in response to cancer vaccines targeting neoantigens.